Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
24
MRKR Quote, Financials, Valuation and Earnings
Last price:
$1.43
Seasonality move
:
11.17%
Day range:
$1.34 - $1.54
52-week range:
$0.81 - $4.07
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.96x
P/B ratio:
1.32x
Volume:
440.6K
Avg. volume:
485.4K
1-year change:
-5.81%
Market cap:
$24.3M
Revenue:
$6.6M
EPS (TTM):
-$1.23
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MRKR
Marker Therapeutics, Inc.
|
$682K | -$0.19 | -69.71% | -54.94% | $7.87 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
ADMA
ADMA Biologics, Inc.
|
$139.8M | $0.20 | 23.95% | 81.82% | $25.67 |
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
$200.9M | $0.37 | 52.45% | -62.86% | $55.00 |
|
NBIX
Neurocrine Biosciences, Inc.
|
$789.8M | $2.30 | 35.59% | 2401.52% | $179.59 |
|
VRDN
Viridian Therapeutics, Inc.
|
$15.8M | -$1.00 | -82.64% | -1.73% | $42.06 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MRKR
Marker Therapeutics, Inc.
|
$1.46 | $7.87 | $24.3M | -- | $0.00 | 0% | 3.96x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.47 | $31.21 | $3.8B | 14.46x | $0.00 | 0% | 3.61x |
|
ADMA
ADMA Biologics, Inc.
|
$16.28 | $25.67 | $3.9B | 19.12x | $0.00 | 0% | 8.20x |
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
$44.98 | $55.00 | $3.4B | 100.33x | $0.00 | 0% | 5.76x |
|
NBIX
Neurocrine Biosciences, Inc.
|
$137.44 | $179.59 | $13.7B | 32.82x | $0.00 | 0% | 5.24x |
|
VRDN
Viridian Therapeutics, Inc.
|
$30.07 | $42.06 | $2.9B | -- | $0.00 | 0% | 34.49x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MRKR
Marker Therapeutics, Inc.
|
-- | 2.330 | -- | 5.66x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -3.277 | 2.38% | 3.53x |
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
1.78% | -0.635 | 0.33% | 3.27x |
|
NBIX
Neurocrine Biosciences, Inc.
|
13.77% | 1.856 | 3.43% | 2.89x |
|
VRDN
Viridian Therapeutics, Inc.
|
4.52% | 1.855 | 1.21% | 11.06x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MRKR
Marker Therapeutics, Inc.
|
-- | -$2.1M | -103.04% | -103.04% | -173.31% | -$2.7M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
$97.3M | $24M | 7.44% | 7.6% | 13.28% | $33M |
|
NBIX
Neurocrine Biosciences, Inc.
|
$780.9M | $239.3M | 13.56% | 15.8% | 30.1% | $214.3M |
|
VRDN
Viridian Therapeutics, Inc.
|
$70.3M | -$40M | -46.01% | -47.79% | -56.7% | -$84.7M |
Marker Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns MRKR or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -162.11% compared to Marker Therapeutics, Inc.'s net margin of 25.76%. Marker Therapeutics, Inc.'s return on equity of -103.04% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital MRKRMarker Therapeutics, Inc.-- -$0.12 $18.4M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About MRKR or ACAD?
Marker Therapeutics, Inc. has a consensus price target of $7.87, signalling upside risk potential of 438.81%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 38.9%. Given that Marker Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MRKRMarker Therapeutics, Inc.3 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is MRKR or ACAD More Risky?
Marker Therapeutics, Inc. has a beta of 1.442, which suggesting that the stock is 44.218% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock MRKR or ACAD?
Marker Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marker Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRKR or ACAD?
Marker Therapeutics, Inc. quarterly revenues are $1.2M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Marker Therapeutics, Inc.'s net income of -$2M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Marker Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 14.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marker Therapeutics, Inc. is 3.96x versus 3.61x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRKRMarker Therapeutics, Inc.3.96x -- $1.2M -$2M ACADACADIA Pharmaceuticals, Inc.3.61x 14.46x $278.6M $71.8M
-
Which has Higher Returns MRKR or ADMA?
ADMA Biologics, Inc. has a net margin of -162.11% compared to Marker Therapeutics, Inc.'s net margin of 27.14%. Marker Therapeutics, Inc.'s return on equity of -103.04% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital MRKRMarker Therapeutics, Inc.-- -$0.12 $18.4M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About MRKR or ADMA?
Marker Therapeutics, Inc. has a consensus price target of $7.87, signalling upside risk potential of 438.81%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 57.66%. Given that Marker Therapeutics, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than ADMA Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MRKRMarker Therapeutics, Inc.3 0 0 ADMAADMA Biologics, Inc.3 0 0 -
Is MRKR or ADMA More Risky?
Marker Therapeutics, Inc. has a beta of 1.442, which suggesting that the stock is 44.218% more volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.502%.
-
Which is a Better Dividend Stock MRKR or ADMA?
Marker Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marker Therapeutics, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRKR or ADMA?
Marker Therapeutics, Inc. quarterly revenues are $1.2M, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Marker Therapeutics, Inc.'s net income of -$2M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Marker Therapeutics, Inc.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 19.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marker Therapeutics, Inc. is 3.96x versus 8.20x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRKRMarker Therapeutics, Inc.3.96x -- $1.2M -$2M ADMAADMA Biologics, Inc.8.20x 19.12x $134.2M $36.4M
-
Which has Higher Returns MRKR or KNSA?
Kiniksa Pharmaceuticals International Plc has a net margin of -162.11% compared to Marker Therapeutics, Inc.'s net margin of 10.19%. Marker Therapeutics, Inc.'s return on equity of -103.04% beat Kiniksa Pharmaceuticals International Plc's return on equity of 7.6%.
Company Gross Margin Earnings Per Share Invested Capital MRKRMarker Therapeutics, Inc.-- -$0.12 $18.4M KNSAKiniksa Pharmaceuticals International Plc53.78% $0.23 $545.1M -
What do Analysts Say About MRKR or KNSA?
Marker Therapeutics, Inc. has a consensus price target of $7.87, signalling upside risk potential of 438.81%. On the other hand Kiniksa Pharmaceuticals International Plc has an analysts' consensus of $55.00 which suggests that it could grow by 22.28%. Given that Marker Therapeutics, Inc. has higher upside potential than Kiniksa Pharmaceuticals International Plc, analysts believe Marker Therapeutics, Inc. is more attractive than Kiniksa Pharmaceuticals International Plc.
Company Buy Ratings Hold Ratings Sell Ratings MRKRMarker Therapeutics, Inc.3 0 0 KNSAKiniksa Pharmaceuticals International Plc6 0 0 -
Is MRKR or KNSA More Risky?
Marker Therapeutics, Inc. has a beta of 1.442, which suggesting that the stock is 44.218% more volatile than S&P 500. In comparison Kiniksa Pharmaceuticals International Plc has a beta of 0.060, suggesting its less volatile than the S&P 500 by 94.045%.
-
Which is a Better Dividend Stock MRKR or KNSA?
Marker Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kiniksa Pharmaceuticals International Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marker Therapeutics, Inc. pays -- of its earnings as a dividend. Kiniksa Pharmaceuticals International Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRKR or KNSA?
Marker Therapeutics, Inc. quarterly revenues are $1.2M, which are smaller than Kiniksa Pharmaceuticals International Plc quarterly revenues of $180.9M. Marker Therapeutics, Inc.'s net income of -$2M is lower than Kiniksa Pharmaceuticals International Plc's net income of $18.4M. Notably, Marker Therapeutics, Inc.'s price-to-earnings ratio is -- while Kiniksa Pharmaceuticals International Plc's PE ratio is 100.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marker Therapeutics, Inc. is 3.96x versus 5.76x for Kiniksa Pharmaceuticals International Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRKRMarker Therapeutics, Inc.3.96x -- $1.2M -$2M KNSAKiniksa Pharmaceuticals International Plc5.76x 100.33x $180.9M $18.4M
-
Which has Higher Returns MRKR or NBIX?
Neurocrine Biosciences, Inc. has a net margin of -162.11% compared to Marker Therapeutics, Inc.'s net margin of 26.36%. Marker Therapeutics, Inc.'s return on equity of -103.04% beat Neurocrine Biosciences, Inc.'s return on equity of 15.8%.
Company Gross Margin Earnings Per Share Invested Capital MRKRMarker Therapeutics, Inc.-- -$0.12 $18.4M NBIXNeurocrine Biosciences, Inc.98.24% $2.04 $3.5B -
What do Analysts Say About MRKR or NBIX?
Marker Therapeutics, Inc. has a consensus price target of $7.87, signalling upside risk potential of 438.81%. On the other hand Neurocrine Biosciences, Inc. has an analysts' consensus of $179.59 which suggests that it could grow by 30.67%. Given that Marker Therapeutics, Inc. has higher upside potential than Neurocrine Biosciences, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than Neurocrine Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MRKRMarker Therapeutics, Inc.3 0 0 NBIXNeurocrine Biosciences, Inc.19 4 0 -
Is MRKR or NBIX More Risky?
Marker Therapeutics, Inc. has a beta of 1.442, which suggesting that the stock is 44.218% more volatile than S&P 500. In comparison Neurocrine Biosciences, Inc. has a beta of 0.311, suggesting its less volatile than the S&P 500 by 68.878%.
-
Which is a Better Dividend Stock MRKR or NBIX?
Marker Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neurocrine Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marker Therapeutics, Inc. pays -- of its earnings as a dividend. Neurocrine Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRKR or NBIX?
Marker Therapeutics, Inc. quarterly revenues are $1.2M, which are smaller than Neurocrine Biosciences, Inc. quarterly revenues of $794.9M. Marker Therapeutics, Inc.'s net income of -$2M is lower than Neurocrine Biosciences, Inc.'s net income of $209.5M. Notably, Marker Therapeutics, Inc.'s price-to-earnings ratio is -- while Neurocrine Biosciences, Inc.'s PE ratio is 32.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marker Therapeutics, Inc. is 3.96x versus 5.24x for Neurocrine Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRKRMarker Therapeutics, Inc.3.96x -- $1.2M -$2M NBIXNeurocrine Biosciences, Inc.5.24x 32.82x $794.9M $209.5M
-
Which has Higher Returns MRKR or VRDN?
Viridian Therapeutics, Inc. has a net margin of -162.11% compared to Marker Therapeutics, Inc.'s net margin of -49.03%. Marker Therapeutics, Inc.'s return on equity of -103.04% beat Viridian Therapeutics, Inc.'s return on equity of -47.79%.
Company Gross Margin Earnings Per Share Invested Capital MRKRMarker Therapeutics, Inc.-- -$0.12 $18.4M VRDNViridian Therapeutics, Inc.99.56% -$0.42 $526.8M -
What do Analysts Say About MRKR or VRDN?
Marker Therapeutics, Inc. has a consensus price target of $7.87, signalling upside risk potential of 438.81%. On the other hand Viridian Therapeutics, Inc. has an analysts' consensus of $42.06 which suggests that it could grow by 39.87%. Given that Marker Therapeutics, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than Viridian Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MRKRMarker Therapeutics, Inc.3 0 0 VRDNViridian Therapeutics, Inc.14 1 0 -
Is MRKR or VRDN More Risky?
Marker Therapeutics, Inc. has a beta of 1.442, which suggesting that the stock is 44.218% more volatile than S&P 500. In comparison Viridian Therapeutics, Inc. has a beta of 0.962, suggesting its less volatile than the S&P 500 by 3.833%.
-
Which is a Better Dividend Stock MRKR or VRDN?
Marker Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viridian Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marker Therapeutics, Inc. pays -- of its earnings as a dividend. Viridian Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRKR or VRDN?
Marker Therapeutics, Inc. quarterly revenues are $1.2M, which are smaller than Viridian Therapeutics, Inc. quarterly revenues of $70.6M. Marker Therapeutics, Inc.'s net income of -$2M is higher than Viridian Therapeutics, Inc.'s net income of -$34.6M. Notably, Marker Therapeutics, Inc.'s price-to-earnings ratio is -- while Viridian Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marker Therapeutics, Inc. is 3.96x versus 34.49x for Viridian Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRKRMarker Therapeutics, Inc.3.96x -- $1.2M -$2M VRDNViridian Therapeutics, Inc.34.49x -- $70.6M -$34.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
40
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
91
TDC alert for Feb 12
Teradata Corp. [TDC] is down 11.64% over the past day.
Buy
67
DIOD alert for Feb 12
Diodes, Inc. [DIOD] is down 7.63% over the past day.
Buy
77
VRT alert for Feb 12
Vertiv Holdings Co. [VRT] is down 4.79% over the past day.
